Phenethyl Isothiocyanate Enhances the Cytotoxic Effects of PARP Inhibitors in High-Grade Serous Ovarian Cancer Cells

被引:9
|
作者
Jia, Yaxun [1 ]
Wang, Min [1 ]
Sang, Xiaolin [1 ]
Liu, Pixu [2 ]
Gao, Jingchun [3 ]
Jiang, Kui [4 ]
Cheng, Hailing [1 ]
机构
[1] Dalian Med Univ, Hosp 2, Dalian Key Lab Mol Targeted Canc Therapy, Canc Inst, Dalian, Peoples R China
[2] Dalian Med Univ, Inst Canc Stem Cell, Dalian, Peoples R China
[3] Dalian Med Univ, Hosp 1, Dept Obstet & Gynecol, Dalian, Peoples R China
[4] Dalian Med Univ, Hosp 2, Dept Med Oncol, Dalian, Peoples R China
来源
FRONTIERS IN ONCOLOGY | 2022年 / 11卷
基金
中国国家自然科学基金;
关键词
BMN; 673; high-grade serous ovarian cancer; PARP inhibitor; phenethyl isothiocyanate; reactive oxygen species; OXIDATIVE STRESS; ORGANIC ISOTHIOCYANATES; THERAPY; RESISTANCE; COMBINATION; ONCOGENE; OLAPARIB;
D O I
10.3389/fonc.2021.812264
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
While PARP inhibitor (PARPi) therapies have shown promising results in the treatment of high-grade serous ovarian cancer (HGSOC) harboring homologous recombination deficiencies, primary resistance to PARPi frequently occurs and even initial responders may eventually become resistant. Therefore, the development of novel effective combinatorial strategies to treat HGSOC is urgently needed. Here, we report that H2O2-induced oxidative stress sensitized HGSOC cells to PARPi BMN 673. Furthermore, Phenethyl isothiocyanate (PEITC) as a ROS-inducing agent significantly enhanced the cytotoxic effects of BMN 673. Mechanistically, combined use of PEITC and BMN 673 resulted in ROS overproduction and accumulation, enhanced DNA damage, G2/M arrest and apoptosis, all of which were significantly reversed by the ROS scavenger N-Acetyl-L-cysteine. We also showed that while PEITC did not further enhance the ability of BMN 673 on PARP1 trapping in HGSOC cells, the therapeutic effects of the PEITC/BMN 673 combination were at least in part dependent on the presence of PARP1. Importantly, the PEITC/BMN 673 combination potently abrogated the growth of HGSOC tumor spheroids and patient-derived organoid models of HGSOC and cervical cancer. Our findings provide a basis for further investigation of the utility of PARPi combination regimen in HGSOC and cervical cancer through ROS-mediated mechanisms.
引用
收藏
页数:13
相关论文
共 50 条
  • [1] PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer
    Morgan, Robert D.
    Clamp, Andrew R.
    Evans, D. Gareth R.
    Edmondson, Richard J.
    Jayson, Gordon C.
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 81 (04) : 647 - 658
  • [2] PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer
    Robert D. Morgan
    Andrew R. Clamp
    D. Gareth R. Evans
    Richard J. Edmondson
    Gordon C. Jayson
    [J]. Cancer Chemotherapy and Pharmacology, 2018, 81 : 647 - 658
  • [3] PARP Inhibitors Display Differential Efficacy in Models of BRCA Mutant High-Grade Serous Ovarian Cancer
    Dickson, Kristie-Ann
    Xie, Tao
    Evenhuis, Christian
    Ma, Yue
    Marsh, Deborah J.
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (16)
  • [4] Crizotinib and PARP inhibitors act synergistically by triggering apoptosis in high-grade serous ovarian cancer (HGSOC)
    Durmaz, Irem
    Hedenfalk, Ingrid
    [J]. CANCER RESEARCH, 2018, 78 (13)
  • [5] Emerging Therapies in the Management of High-Grade Serous Ovarian Carcinoma: a Focus on PARP Inhibitors
    Karime Kalil Machado
    Stéphanie L. Gaillard
    [J]. Current Obstetrics and Gynecology Reports, 2017, 6 (3) : 207 - 218
  • [6] ELUCIDATING RESISTANCE MECHANISM TO PARP INHIBITORS FOR THE DEVELOPMENT OF NOVEL THERAPEUTIC APPROACHES IN HIGH-GRADE SEROUS OVARIAN CANCER
    Kulbe, Hagen
    Kassuhn, Wanja
    Ringel, Frauke
    Welsch, Gabriele
    Treffkorn, Peggy
    Taube, Eliane
    Horst, David
    Sehouli, Jalid
    Braicu, Elena
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2020, 30 : A79 - A79
  • [7] Proteases and their inhibitors as prognostic factors for high-grade serous ovarian cancer
    Trudel, Dominique
    Avarvarei, Luminita-Mihaela
    Orain, Michele
    Turcotte, Stephane
    Plante, Marie
    Gregoire, Jean
    Kappelhoff, Reinhild
    Labbe, David P.
    Bachvarov, Dimcho
    Tetu, Bernard
    Overall, Christopher M.
    Bairati, Isabelle
    [J]. PATHOLOGY RESEARCH AND PRACTICE, 2019, 215 (06)
  • [8] Exploring the Control of PARP1 Levels in High-Grade Serous Ovarian Cancer
    Raspaglio, Giuseppina
    Buttarelli, Marianna
    Cappoli, Natalia
    Ciucci, Alessandra
    Fagotti, Anna
    Scambia, Giovanni
    Gallo, Daniela
    [J]. CANCERS, 2023, 15 (08)
  • [9] Efficacy of PARP inhibitors in advanced high-grade serous ovarian cancer according to BRCA domain mutations and mutation type
    Buonaiuto, Roberto
    Neola, Giuseppe
    Caltavituro, Aldo
    Longobardi, Alessandra
    Mangiacotti, Federica Pia
    Cefaliello, Amedeo
    Lamia, Maria Rosaria
    Pepe, Francesco
    Ventriglia, Jole
    Malapelle, Umberto
    Troncone, Giancarlo
    Giuliano, Mario
    Arpino, Grazia
    Pignata, Sandro
    De Angelis, Carmine
    [J]. FRONTIERS IN ONCOLOGY, 2024, 14
  • [10] Elucidating resistance mechanism to PARP inhibitors for the development of novel therapeutic approaches in high-grade serous ovarian cancer.
    Kulbe, Hagen
    Kassuhn, Wanja Nikolai
    Ringel, Frauke
    Welsch, Gabriele
    Treffkorn, Peggy
    Taube, Eliane T.
    Horst, David
    Sehouli, Jalid
    Braicu, Ioana
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)